Search

Displaying results 1401 - 1410 of 4539 in total
  1. Drug

    Triamterene

    go.drugbank.com/drugs/DB00384
    Approved

    It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. … [L6163] Triamterene was approved by the Food and Drug Administration in the U.S. in 1964.

    Categories: Decreased Renal K+ Excretion
  2. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes. … [A256408] By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and increases urinary glucose excretion, which reduces blood glucose levels independently of insulin sensitivity

  3. Drug

    Cefmetazole

    go.drugbank.com/drugs/DB00274
    Approved

    A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been n...

  4. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]

  5. Drug

    Diltiazem

    go.drugbank.com/drugs/DB00343
    ApprovedInvestigational

    It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization. … Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class.

  6. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell

    Categories: MATE 2-K Inhibitors
  7. Drug

    Lindane

    go.drugbank.com/drugs/DB00431
    ApprovedWithdrawn

    In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical

  8. Drug

    Artemether

    go.drugbank.com/drugs/DB06697
    ApprovedInvestigational

    </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

  9. Drug

    Temozolomide

    go.drugbank.com/drugs/DB00853
    ApprovedInvestigational

    [A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow … It is currently marketed under the trademark TEMODAR® by Merck.[L32033]

  10. Drug

    Tyrosine

    go.drugbank.com/drugs/DB00135
    ApprovedInvestigationalNutraceutical

    Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.